167 related articles for article (PubMed ID: 36459492)
1. Ethnicity in polycystic ovary syndrome.
Shah D; Rasool S
Climacteric; 2023 Feb; 26(1):15-20. PubMed ID: 36459492
[TBL] [Abstract][Full Text] [Related]
2. Cardiometabolic biomarkers in women with polycystic ovary syndrome.
van der Ham K; Louwers YV; Laven JSE
Fertil Steril; 2022 May; 117(5):887-896. PubMed ID: 35512973
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovary syndrome and metabolic syndrome.
Ali AT
Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran.
Tehrani FR; Rashidi H; Khomami MB; Tohidi M; Azizi F
Reprod Biol Endocrinol; 2014 Sep; 12():89. PubMed ID: 25224635
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovarian syndrome.
Khan KA; Stas S; Kurukulasuriya LR
J Cardiometab Syndr; 2006; 1(2):125-30; quiz 131-2. PubMed ID: 17679815
[TBL] [Abstract][Full Text] [Related]
7. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
[TBL] [Abstract][Full Text] [Related]
8. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype.
Engmann L; Jin S; Sun F; Legro RS; Polotsky AJ; Hansen KR; Coutifaris C; Diamond MP; Eisenberg E; Zhang H; Santoro N;
Am J Obstet Gynecol; 2017 May; 216(5):493.e1-493.e13. PubMed ID: 28104402
[TBL] [Abstract][Full Text] [Related]
9. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.
Rasool SUA; Ashraf S; Nabi M; Rashid F; Fazili KM; Amin S
Diabetes Metab Syndr; 2019; 13(3):2098-2105. PubMed ID: 31235143
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals.
Becerra-Fernández A; Pérez-López G; Román MM; Martín-Lazaro JF; Lucio Pérez MJ; Asenjo Araque N; Rodríguez-Molina JM; Berrocal Sertucha MC; Aguilar Vilas MV
Endocrinol Nutr; 2014; 61(7):351-8. PubMed ID: 24680383
[TBL] [Abstract][Full Text] [Related]
11. Heart health in polycystic ovary syndrome: time to act on the data.
Dokras A
Fertil Steril; 2022 May; 117(5):885-886. PubMed ID: 35512972
[TBL] [Abstract][Full Text] [Related]
12. Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.
Albu A; Radian S; Fica S; Barbu CG
Endocrine; 2015 Mar; 48(2):696-704. PubMed ID: 25022659
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome and hyperandrogenism as a risk factor for cardiovascular disease.
Martikainen H; Ruokonen A; Hartikainen AL; Järvelin MR
Int J Circumpolar Health; 1998 Jul; 57(2-3):133-7. PubMed ID: 9753881
[TBL] [Abstract][Full Text] [Related]
14. Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Bjekić-Macut J; Vukašin T; Velija-Ašimi Z; Bureković A; Zdravković M; Andrić Z; Branković M; Crevar-Marinović S; Madić T; Stanojlović O; Milutinović DV; Livadas S; Mastorakos G
Curr Pharm Des; 2021; 27(36):3812-3820. PubMed ID: 33463457
[TBL] [Abstract][Full Text] [Related]
15. [Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents].
Silva Rdo C; Pardini DP; Kater CE
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):281-90. PubMed ID: 16767294
[TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic risks in PCOS: a review of the current state of knowledge.
Kakoly NS; Moran LJ; Teede HJ; Joham AE
Expert Rev Endocrinol Metab; 2019 Jan; 14(1):23-33. PubMed ID: 30556433
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk factors and events in women with androgen excess.
Macut D; Antić IB; Bjekić-Macut J
J Endocrinol Invest; 2015 Mar; 38(3):295-301. PubMed ID: 25432327
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome.
Krentowska A; Kowalska I
Diabetes Metab Res Rev; 2022 Jan; 38(1):e3464. PubMed ID: 33988288
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
Alemzadeh R; Kichler J; Calhoun M
Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
[TBL] [Abstract][Full Text] [Related]
20. Metabolic inflexibility in women with polycystic ovary syndrome: a systematic review.
Rimmer M; Tan BK; Teede H; Thangaratinam S; H Al Wattar B
Gynecol Endocrinol; 2020 Jun; 36(6):501-507. PubMed ID: 31793357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
